Supplementation with a 9c,11t-rich conjugated XXXX blend shows no clear inhibitory effects on platelet function in healthy subjects at low and moderate cardiovascular risk: A randomized controlled trial.

@entity1 @entity32 @entity2870 @entity4619 @entity2842 @entity8729 @entity65 @entity4722
SCOPE: The 9cis,11trans-conjugated @entity4722 (9c,11t- @entity4619 ) is reported to have anti-atherogenic properties in animal models and to modulate protein expression in unstimulated @entity1 platelets in vivo. Platelet function was therefore investigated after dietary supplementation with 9c,11t- @entity4619 enriched oil (CLA80:20) in a randomized, baseline-controlled cross-over trial. METHODS AND RESULTS: Forty-three healthy adults at low to moderate risk of @entity65 received 4 g/day of CLA80:20 or placebo for two weeks each. Platelet function, @entity32 , and endothelial activation were assessed before and after each phase. Compared with placebo, supplementation had no significant effects on platelet function measured by Platelet Function Analyzer-100. Inhibitory effects on collagen-induced aggregation were sex-dependent (p  =  0.005) that reached significance only in @entity1 (p  =  0.045). @entity2870 ( @entity2870 )-induced @entity8729 expression was higher after supplementation in all subjects (p  =  0.017). @entity2870 -induced platelet fibrinogen binding was also dependent on sex (p = 0.015), with fibrinogen binding after CLA80:20 being higher in males (p  =  0.035). Plasma @entity2842 was higher (p  =  0.041) after CLA80:20. CONCLUSION: No clear evidence was found for inhibition or activation of platelet function as well as @entity32 by CLA80:20 in a low to moderate cardiovascular risk group.
